Gene testing in triple negative breast cancer at two points: before and after chemotherapy
Not Applicable
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2022/05/042779
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with triple negative breast cancer
Non metastatic disease
Planned for neoadjuvant chemotherapy
Willing to participate in study
Exclusion Criteria
Patients with prior history of cancer
Patients planned for upfront surgery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of targetable mutations in residual disease in triple negative breast cancer that were not initially present in the tumor cells and in germlineTimepoint: Six months
- Secondary Outcome Measures
Name Time Method Identifying the associations between differential mutations with disease-free survival of patients with triple negative breast cancer <br/ ><br> <br/ ><br>Identification of genetic mutations associated with incomplete response to chemotherapy <br/ ><br> <br/ ><br>Identification of new mutations that develop in recurrent disease <br/ ><br>Timepoint: Six months